Free Trial

Life360 (LIF) Competitors

Life360 logo
$45.61 -1.25 (-2.67%)
As of 03:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LIF vs. RTO, CART, FTAI, ALLE, ULS, MEDP, WPP, HQY, GLOB, and BILI

Should you be buying Life360 stock or one of its competitors? The main competitors of Life360 include Rentokil Initial (RTO), Maplebear (CART), FTAI Aviation (FTAI), Allegion (ALLE), UL Solutions (ULS), Medpace (MEDP), WPP (WPP), HealthEquity (HQY), Globant (GLOB), and Bilibili (BILI). These companies are all part of the "business services" industry.

Life360 vs.

Rentokil Initial (NYSE:RTO) and Life360 (NASDAQ:LIF) are both business services companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, Life360 had 1 more articles in the media than Rentokil Initial. MarketBeat recorded 4 mentions for Life360 and 3 mentions for Rentokil Initial. Life360's average media sentiment score of 1.36 beat Rentokil Initial's score of 1.27 indicating that Life360 is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rentokil Initial
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Life360
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Life360 received 11 more outperform votes than Rentokil Initial when rated by MarketBeat users. Likewise, 83.33% of users gave Life360 an outperform vote while only 30.77% of users gave Rentokil Initial an outperform vote.

CompanyUnderperformOutperform
Rentokil InitialOutperform Votes
4
30.77%
Underperform Votes
9
69.23%
Life360Outperform Votes
15
83.33%
Underperform Votes
3
16.67%

Rentokil Initial has higher revenue and earnings than Life360.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rentokil Initial$6.68B1.98$473.93MN/AN/A
Life360$304.52M11.49-$28.17MN/AN/A

Rentokil Initial has a net margin of 0.00% compared to Life360's net margin of -4.72%. Rentokil Initial's return on equity of 0.00% beat Life360's return on equity.

Company Net Margins Return on Equity Return on Assets
Rentokil InitialN/A N/A N/A
Life360 -4.72%-4.03%-3.16%

Life360 has a consensus target price of $47.63, suggesting a potential upside of 1.63%. Given Life360's stronger consensus rating and higher possible upside, analysts plainly believe Life360 is more favorable than Rentokil Initial.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rentokil Initial
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.71
Life360
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

9.9% of Rentokil Initial shares are owned by institutional investors. Comparatively, 20.0% of Life360 shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Life360 beats Rentokil Initial on 9 of the 15 factors compared between the two stocks.

Get Life360 News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIF vs. The Competition

MetricLife360Data processing & preparation IndustryIndustrial SectorNASDAQ Exchange
Market Cap$3.58B$4.46B$9.22B$9.20B
Dividend YieldN/A2.63%2.09%3.85%
P/E RatioN/A53.0514.1014.11
Price / Sales11.497.554.3779.70
Price / CashN/A34.8922.2637.47
Price / BookN/A6.544.594.77
Net Income-$28.17M$38.21M$424.79M$245.88M
7 Day Performance0.86%-0.94%-0.80%-0.90%
1 Month Performance4.72%0.46%-3.97%-0.52%
1 Year PerformanceN/A19.15%32.65%16.50%

Life360 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LIF
Life360
1.5711 of 5 stars
$45.61
-2.7%
$47.63
+4.4%
N/A$3.40B$304.52M0.00600Positive News
RTO
Rentokil Initial
1.6087 of 5 stars
$27.04
+2.1%
N/A-3.8%$13.65B$5.41B0.0062,900Positive News
Gap Up
CART
Maplebear
2.5756 of 5 stars
$50.97
+2.0%
$48.96
-3.9%
+89.7%$13.09B$3.04B34.213,380
FTAI
FTAI Aviation
4.1361 of 5 stars
$113.59
+5.3%
$171.75
+51.2%
+171.9%$11.65B$1.17B-1,135.7940
ALLE
Allegion
4.2836 of 5 stars
$133.51
+0.3%
$140.83
+5.5%
-3.8%$11.61B$3.65B20.5112,400Earnings Report
Analyst Forecast
ULS
UL Solutions
1.768 of 5 stars
$56.71
-1.1%
$49.00
-13.6%
N/A$11.35B$2.68B0.0015,233Earnings Report
Analyst Forecast
News Coverage
MEDP
Medpace
4.2298 of 5 stars
$340.17
-0.7%
$381.44
+12.1%
-10.2%$10.57B$1.89B29.795,200
WPP
WPP
0.7997 of 5 stars
$48.31
-1.1%
N/A-4.2%$10.42B$18.46B0.00114,732Upcoming Earnings
HQY
HealthEquity
2.1031 of 5 stars
$112.69
-1.1%
$110.71
-1.8%
+37.4%$9.77B$999.59M103.393,150Positive News
GLOB
Globant
4.7556 of 5 stars
$224.28
-1.9%
$230.28
+2.7%
-5.3%$9.66B$2.10B58.5629,150Earnings Report
Analyst Forecast
News Coverage
Gap Down
BILI
Bilibili
1.4881 of 5 stars
$21.99
+10.9%
$19.69
-10.5%
+116.8%$9.11B$3.19B-23.908,801Earnings Report
Analyst Forecast
Options Volume
News Coverage
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:LIF) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners